An oncologist ruminates on emerging treatment options in follicular lymphoma and offers some clinical pearls.
Alan Skarbnik, MD
Advertisement
Alan Skarbnik, MD, serves as the director of the lymphoma and chronic lymphocytic leukemia program and director of experimental therapeutics, malignant hematology at Novant Health.
Articles by Alan Skarbnik, MD
Alan Skarbnik, MD, explains early relapse in follicular lymphoma and the available treatment options.
An expert describes typical monitoring strategies in follicular lymphoma.
Dr. Alan Skarbnik reviews the use of obinutuzumab-based therapies for follicular lymphoma and highlights data from a phase III study.
A key opinion leader discusses the considerations in choosing induction and maintenance therapy options for follicular lymphoma.
Alan Skarbnik, MD, presents the case of a 60-year-old man with newly diagnosed follicular lymphoma.
Alan Skarbnik, MD, director of the Chronic Lymphocytic Leukemia Program at John Theurer Cancer Center, discusses the possibility of triplet combinations for the treatment of hematologic malignances. The biggest challenge with this type of treatment regimen is the increased risk of adverse events.
Advertisement
Latest Updated Articles
Follicular Lymphoma: Emerging TreatmentsPublished: October 11th 2021 | Updated:
- Induction Therapy Options in Follicular Lymphoma
Published: October 11th 2021 | Updated:
- Monitoring Strategies in Follicular Lymphoma
Published: October 11th 2021 | Updated:
Challenges With Triplet Regimens for the Treatment of Hematologic MalignanciesPublished: April 18th 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
